BACKGROUND Despite extensive clinical experience with onabotulinumtoxinA, few data exist on patient satisfaction or safety with continuous treatment.
T he first reports of onabotulinumtoxinA (Botox Cosmetic; Allergan, Inc., Irvine, CA) injection for aesthetic purposes were published in the early 1990s, 1 with results of the first clinical trials published a decade later. 2, 3 The US regulatory approval for the treatment of glabellar lines (GL) was granted in 2002, 4 and the efficacy and safety of onabotulinumtoxinA for aesthetic purposes are now well established. 5, 6 Other aesthetic uses of onabotulinumtoxinA, alone or in combination with other procedures, are now commonplace for the upper and lower face, including treatment of crow's feet lines (CFL; US approval granted in 2013) and forehead lines (FHL). 4, [7] [8] [9] Patient satisfaction with an aesthetic procedure is critical to determining treatment success. [10] [11] [12] Selfimage is a key motivator for patients deciding to undergo aesthetic procedures, and outcomes are strongly associated with changes in self-esteem that drive patient satisfaction. [13] [14] [15] In clinical trials of onabotulinumtoxinA, patient satisfaction has been high but not rigorously documented over a long period, 16 with the longest period being a prospective 26-month study showing progressively increasing patient satisfaction across 6 treatment cycles. 17 Despite widespread clinical experience with onabot-ulinumtoxinA, there are little data on its long-term safety because of the generally short duration of randomized controlled trials that frequently investigated only a single treatment cycle. 2, 9 The purpose of this international multicenter study was to evaluate long-term patient satisfaction and safety of facial aesthetic treatment with onabotuli-numtoxinA in patients after 5 or more years of continuous treatment. The evolution of practice patterns over time with onabotulinumtoxinA will be reported in a separate publication.
Methods

Study Design and Patients
This was an international, multicenter, retrospective chart review with a cross-sectional analysis conducted at 11 sites in the United States, Canada, France, Brazil, and Australia. The study was conducted in accordance with Institutional Review Board or Independent Ethics Committee approval. Patient charts at each site were reviewed for eligibility, and patients were subsequently contacted to see if they were interested in participating in the study. Interested patients were scheduled for an in-clinic visit during which they provided written informed consent before collection of their treatment history and completion of the study questionnaires. Patients attended 1 study visit between 4 and 28 weeks after their last GL treatment.
Eligible patients were aged 18 years or older at the time of their first aesthetic treatment with onabotuli-numtoxinA, had a history of 5 or more years of continuous onabotulinumtoxinA treatments (with a yearly average of 2 or more treatments, including at least 1 GL treatment per year for 5 or more years), treated by the same physician, and received only onabotulinumtoxinA. Patients were ineligible if they had received other neuromodulator treatments or had aesthetic surgery that could interfere with treatment outcomes.
Chart Review
Chart reviews were conducted for all enrolled patients. Data collected included demographics, onabotulinumtoxinA treatment history (comprising facial treatment areas, number of treatments, and doses per treatment visit), concomitant facial aesthetic procedures and treatments, and documented adverse events (AEs) related to onabotulinumtoxinA treatment.
Patient-Reported Outcomes
At the study visit, each patient completed 4 separate questionnaires. The 13-item Facial Line Satisfaction Questionnaire Follow-Up Version (FLSQ) was used to assess treatment satisfaction, treatment expectations, and impact of treatment on GL. Patients were asked to respond to the questions based on assessment of their GL only. The single-item Self-Perception of Age (SPA) measure ("How do you think your facial appearance looks compared to your age today?") was used to assess the relationship of patients' facial appearance (CFL, FHL, and GL together) and their chronological age. 18 The 11-item Facial Line Outcomes questionnaire (FLO-11) was used to determine the appearance of facial lines (CFL, FHL, and GL together). 19 Finally, a single-item de novo questionnaire, the Patient-Reported Overall Satisfaction of Effectiveness ("How satisfied overall are you with the
effect of onabotulinumtoxinA?"), was used to assess patients' overall satisfaction of effectiveness with 5 or more years of continued onabotulinumtoxinA treatments. The FLSQ, SPA, and FLO-11 are validated instruments developed in accordance with the US Food and Drug Administration Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 20 
Outcome Measures and Analyses
The primary end point for this analysis was patient satisfaction with the effect of treatment on GL, assessed at the cross-sectional study visit and measured by Item 5 of the FLSQ (How satisfied are you with the effect your treatment had on your facial lines?); patient satisfaction was defined as the proportion of patients who responded "mostly satisfied" and "very satisfied." Other end points included appearance-related and age-related impacts of upper facial lines as measured by the total FLO-11 score and SPA, respectively; additional components of treatment satisfaction were measured by the Patient-Reported Overall Satisfaction of Effectiveness questionnaire and the Physician-Reported Overall Satisfaction of Effectiveness questionnaire (which posed the same question to treating physicians) and the remaining questions in the FLSQ. Total FLO-11 score was calculated as the sum of the means of the reverse scores (i.e., 10 minus the original score) of Items 1 to 10 plus the mean score of Item 11. The FLO-11 total score was then transformed to a 0-point (worst) to 100-point (best) scale. Summary tables and descriptive statistics were used in the presentation of results.
Results
Patients and Treatments
A total of 207 patients participated in the study and constitute the intent-to-treat/safety population. A small number of patients (n = 13) had been treated for less than 5 years or had missing FLSQ data, resulting in a per protocol (PP) population of 194. Demographic characteristics of these 2 populations were similar ( Table 1 ). The mean time span between the first GL treatment and the most recent GL treatment in the PP population was 9.1 6 2.9 years, with a range from 5.0 to 16.8 years.
Treatment History
Patients in the PP population had a cumulative total of 4,402 GL treatments with onabotulinumtoxinA, with a mean 6 SD of 22.7 6 8.7 injections at a mean dose of 21.6 6 10.8 U. In addition, 92.3% (179/194) received treatment for CFL at a mean dose of 19.4 6 8.6 U, and 90.7% (176/194) received treatment for FHL at a mean dose of 9.0 6 5.6 U. Some patients also received onabotulinumtoxinA treatments for bunny lines, perioral lines, and the chin ( Table 2 ). The mean dose per visit per patient for each study site ranged from 13.9 to 33.1 U for GL, 14.5 to 28.4 U for CFL, and 5.3 to 16.0 U for FHL. The total number of onabotulinumtoxinA treatment sessions was 5,112, with some treatment sessions involving injections of onabotulinumtoxinA in more than 1 facial region (Table 3) . 
Concomitant Procedures
Most patients underwent additional facial aesthetic procedures in addition to onabotuli-numtoxinA injections, with 85.1% receiving 1 or more treatments with an injectable filler and 60.8% receiving 6 or more treatments (Table 4 ). Hyaluronic acid fillers were the most common (82.0% of patients with 1 or more treatments). Other frequent concomitant facial aesthetic procedures included prescription topical creams and energy-based devices.
Satisfaction With Long-Term Treatment
Facial Line Satisfaction Questionnaire For the primary end point (response to FLSQ Item 5), 92.3% of patients (179/194) were "mostly satisfied" (36.1%; n = 70) or "very satisfied" (56.2%; n = 109) with the effects of treatment on GL after 5 or more years of continuous onabotulinumtoxinA. As the FLSQ was administered between 4 and 28 weeks after the last treatment, the effect of time since treatment on the primary end point was investigated. Results of this analysis indicated that patient satisfaction with treatment was not influenced by the time between treatment and administration of the questionnaire when examined in 4-week increments (data not shown). Of those who had received concomitant injectable filler treatments (n = 165; facial areas of treatments were not recorded), 93.3% were "mostly satisfied" or "very satisfied," and of those who did not have injectable filler treatments (n = 29), 86.2% were "mostly satisfied" or "very satisfied." No formal statistical comparison of patients who received concomitant injectable fillers and those who did not was performed because of the imbalance in the numbers of patients in each group. However, confidence intervals for the 2 groups overlapped, suggesting that there were no differences between these 2 groups. Favorable responses ("very satisfied" and "mostly satisfied," "quite a bit," "extremely," "met expectation," and "better than expected") to other questions on the FLSQ, including time treatment took to work, lasting effects of results, natural look of treatment, appearance, desire to continue treatment, and meeting expectations, ranged from 82.5% to 99.5% of patients.
Self-Perception of Age
Almost all patients (99.5%; 193/194) reported looking their current age or younger, with reference to their upper face appearance (CFL, FHL, and GL together), after at least 5 years of continuous treatment. Among 89.7% of patients (174/194) who reported looking younger, the mean 6 SD perceived age was 6.9 6 2.9 years younger and improved with increasing years of onabotulinumtoxinA treatment (Figure 1 ). 
Other Questionnaires
The mean total 6 SD FLO-11 score was 65.7 6 23.6 (with higher scores indicating improvement in appearance-related outcomes). The time span between the last GL injection and when the FLO-11 questionnaire was administered did not seem to influence the mean total FLO-11 score when calculated at 4-week increments between 4 and 28 weeks after the last injection. Patient-Reported and Physician-Reported Overall Satisfaction of Effectiveness results indicated that the majority of patients (95.8%; 184/192) and physicians (97.9%; 190/194) were "mostly satisfied" or "very satisfied" with the overall effects of continuous onabotulinumtoxinA treatment ( Figure 2 ).
Safety
OnabotulinumtoxinA was generally well tolerated over the course of 5,292 treatment sessions in the safety population (N = 207), with a total of 82 documented onabotulinumtoxinA-related AEs in 40 patients for an overall rate of 0.015 AEs per treatment session ( Table 5 ). Most AEs were mild and resolved without intervention. Among the 5,292 treatment sessions, there were 8 cases of eyelid ptosis in 7 patients, all of which were considered mild by investigators; 3 of these were treated with iodipine. Adverse events coded to "facial paresis" are summarized in Table 6 . These included the only 2 AEs that were recorded as severe: lip asymmetry and lip paresis occurring 3 years apart in a single patient. Despite this, the patient received onabotulinumtoxinA treatment to the same area in the intervening period. These AEs resolved without sequelae. The remaining facial paresis events were mild or moderate. The number of AEs declined over time, with a marked decrease between the first and second years of treatment (31.7% documented in the first year and 14.6% documented in the second year; Figure 3 ). The change between the first 2 years was driven by a decrease in 1 . Impact of years of onabotulinumtoxinA treatment on perceived age (mean SPA score; PP population, n = 194). Patients receiving treatments for 10 or more years recorded the greatest years younger in perceived age. AEs associated with treatments of the upper face, with 16 AEs in the first year and 5 AEs in the second year. There were 3 AEs in each of the first 2 years for the lower face.
Discussion
This is the first study to evaluate patient satisfaction and safety in a population receiving long-term continuous treatment with onabotulinumtoxinA. These data represent the largest number of treatments in a study to date, with 4,402 GL injections administered at 5,112 treatment sessions to 194 patients with a mean of 22.7 GL treatment cycles per patient over a range of 5 to almost 17 years. This study therefore provides an unprecedented real-world assessment of outcomes after long-term continuous onabotuli-numtoxinA treatment.
Patient satisfaction is important as it is a key driver of real-world treatment success. [10] [11] [12] [13] [14] [15] Uniquely, this study used a cross-sectional analysis to evaluate patient satisfaction and self-perception of age after regular and repeated facial aesthetic treatments. Multiple patient-reported outcome instruments were used, allowing for a rigorous, detailed, and in-depth 
assessment of patient satisfaction and appearancerelated and age-related impacts of upper facial lines after their most recent treatment. The FLSQ results showed that more than 90% of patients were "satisfied" or "very satisfied" with the effect of repeated onabotulinumtoxinA treatment after a mean of 9.1 years. In trials of much shorter duration, patient satisfaction for the treatment of GL with onabotuli-numtoxinA ranged from 71.4% to 95.0% at 1 month and 83.4% to 93.0% at 3 to 4 months using a variety of patient-reported outcome instruments. 16, 21, 22 This study demonstrated patient satisfaction with treatment after 5 or more years of repeated injections with onabotulinumtoxinA. This was reflected in the results from 2 de novo instruments that assessed both patient and physician overall satisfaction with facial aesthetic treatment. Satisfaction levels by both groups were almost complete, with 98.0% of physicians and 95.8% of patients being "mostly satisfied" or "very satisfied" with treatment outcomes. The agreement between patients and physicians reinforces the success of onabotulinumtoxinA treatment in this study. Changes in facial musculature that reduce signs of negative expression (e.g., GL) may lead to improvements in mood, thus offering 1 potential explanation for the high levels of patient satisfaction in this study. [23] [24] [25] [26] [27] In addition, patient satisfaction may have been influenced by onabotulinumtoxinA treatment to multiple facial areas 28 and concomitant facial procedures, suggesting that a comprehensive approach to treatment may be an important factor in determining patient satisfaction with facial appearance.
The combination of several onabotulinumtoxinA treatments administered to CFL and FHL, as well as GL, and other treatment modalities over the long term may have contributed to the remarkable SPA data reported in this study. Although not prospectively studied, it has been suggested previously that a wholeface approach combining treatment modalities may further reduce the appearance of aging. 29 Assessment of the relationship between patients' facial appearance and their age showed that 89.7% perceived that they looked younger than their actual age. This compares with 42% to 75% in shorter studies. 18, 30, 31 These studies also observed a decrease in perceived age by an average of 3 to 4 years, compared with the mean of 6.9 years reported here. 18, 30, 31 The current results suggest that long-term repeated use of ona-botulinumtoxinA, alone or in combination with other facial aesthetic treatments, reinforces the importance of self-image in the continuation of aesthetic procedures. Self-perceived benefits may also be influenced by facial feedback from external sources, such as family or friends. Specifically, a reduction in negative facial expressions may lead to improvements not only in the emotional state of the individual but also the emotional state and facial expression of the onlooker. 32 The FLO-11 score is difficult to fully interpret because of the absence of baseline values for comparison. The mean total score reported does suggest that the patients responded favorably, indicating that their facial lines had a positive impact on their appearance at the time of questionnaire completion. One patient with high satisfaction scores who reported a total FLO-11 score of 0 was thought to have misunderstood the scoring instructions. Despite these issues, the total mean FLO-11 score of 65.7 is comparable with posttreatment results of shorter studies using the same instrument, illustrating the persistence of improved appearance-related outcomes with continuous ona-botulinumtoxinA treatment over a long period. 19, 31 This study provided an in-depth picture of onabotu-linumtoxinA dosing in an in-office setting. For GL, the mean dose per treatment of 21.6 U was close to the labeled dose of 20 U, suggesting that the labeled dose is broadly appropriate in the office setting. However, when stratified by study site, the mean dose per site ranged from 13.9 to 33.1 U, indicating some variability in dosing trends among physicians. Similar observations on the mean range of doses by study site for CFL (14.5-28.4 U) and FHL (5.3-16 .0 U) support this observation.
The AEs recorded in this population were generally mild and typical of those seen in similar clinical trials, including headache and eyelid ptosis. 2, 3 However, the incidence of headache documented here (less than 1%; 1 patient) was much lower than that previously reported in other clinical trials (11.4%-15.3%). 2, 3 Other AEs, coded as facial paresis, were consistent with the known pharmacology of onabotuli-numtoxinA, such as undesirable facial muscle weakening resulting in a "Spock brow"/"Mephisto brow" or lip weakness after treatment in the perioral musculature. The AEs of local muscle weakness were classified together as "facial paresis" as noted in Table 5 , with 11.1% of patients documenting at least 1 episode during the reporting period. However, when averaged across the cumulative number of treatments administered, the actual incidence of such AEs was very low. The decline in AEs observed over time in this study is consistent with results of other onabotulinumtoxinA studies, in both aesthetic and therapeutic indications. 33, 34 This suggests that physicians may refine dose and injection patterns in individual patients to avoid AEs or, alternatively, that patient reporting habits may change over time. Another possible explanation is that the information recorded in patient charts may not be reflective of all AEs experienced by the patient. Adverse events not considered bothersome by patients may not have been reported, and therefore not documented in patient charts. No unexpected onabotulinumtoxinArelated AEs were documented in this study.
This study has several limitations. It was a retrospective study; as such, it is difficult to measure changes in patients' satisfaction with treatment and its relatedness to their quality of life, including its relation to baseline. Study entry criteria required 5 or more years of continuous onabotulinumtoxinA treatment. As a result, patients voluntarily returning for additional treatments most likely self-selected as being both satisfied with and tolerant of initial treatments. However, the choice to continue treatment would likely only occur if patients considered their treatments to produce positive outcomes over time. The perceived improvement in age with increasing years of onabotulinumtoxinA treatment based on SPA lends credence to this hypothesis. The patientreported outcome instruments were administered once and thus evaluated only a single point in time within 28 weeks of the last treatment. Although patients may have received onabotulinumtoxinA treatments to different areas on the face, satisfaction was only assessed for GL, with patients instructed to complete the FLSQ questionnaire based only on their GL. Comprehension of the FLSQ questionnaire and the associated instructions have been demonstrated, based on content validation interviews conducted in the course of the development of this measure. Thus, there is strong evidence that onabotulinumtoxinA treatment of GL resulted in very high satisfaction. However, it is possible that concomitant treatments to other areas of the face may also have contributed to long-term patient satisfaction. Nonetheless, the SPA, FLO-11, and Patient-Reported and Physician-Reported Overall Satisfaction of Effectiveness questionnaires assessed all upper facial lines, allowing a more comprehensive evaluation.
Dosing and results reported in this study are specific to the formulation of botulinum toxin Type A manufactured by Allergan, Inc. This formulation is not interchangeable with other botulinum toxin products, and dosing cannot be converted to that of any other products by the use of a dose ratio.
Conclusion
This is the first study to investigate long-term (mean, 9.1 years) continuous treatment with onabotuli-numtoxinA. The retrospective nature of the study ensured that it represented a real-world experience, with the majority of patients having treatments in multiple areas of the face and additional concomitant facial aesthetic procedures, including injectable fillers, topical creams, and treatment with energy-based devices. Repeated treatment with onabotulinumtox-inA, alone or in combination with other facial aesthetic treatments, was safe in that AEs were infrequent and decreased substantially after the first 1 to 2 years. Long-term treatment was associated with a high degree of patient and physician satisfaction at the time of assessment using a variety of tools, including validated patient-reported outcome instruments. These are critical findings, as high patient satisfaction and improvements in self-image are perhaps the most important outcomes and motivators for aesthetic procedures. [10] [11] [12] Reasons for the high patient satisfaction and remarkable SPA results reported by patients in this study are likely multifactorial and reflect the complex association of appearance, selfimage, and self-esteem.
